Your browser doesn't support javascript.
loading
Digital biomarkers: 3PM approach revolutionizing chronic disease management - EPMA 2024 position.
Smokovski, Ivica; Steinle, Nanette; Behnke, Andrew; Bhaskar, Sonu M M; Grech, Godfrey; Richter, Kneginja; Niklewski, Günter; Birkenbihl, Colin; Parini, Paolo; Andrews, Russell J; Bauchner, Howard; Golubnitschaja, Olga.
Affiliation
  • Smokovski I; University Clinic of Endocrinology, Diabetes and Metabolic Disorders, Skopje, North Macedonia.
  • Steinle N; Faculty of Medical Sciences, University Goce Delcev, Stip, North Macedonia.
  • Behnke A; Veteran Affairs Capitol Health Care Network, Linthicum, MD USA.
  • Bhaskar SMM; University of Maryland School of Medicine, Baltimore, MD USA.
  • Grech G; Endocrinology Section, Carilion Clinic, Roanoke, VA USA.
  • Richter K; Virginia Tech Carilion School of Medicine, Roanoke, VA USA.
  • Niklewski G; Department of Neurology, Division of Cerebrovascular Medicine and Neurology, National Cerebral and Cardiovascular Centre (NCVC), Suita, Osaka Japan.
  • Birkenbihl C; Department of Neurology & Neurophysiology, Liverpool Hospital, Ingham Institute for Applied Medical Research and South Western Sydney Local Health District, Sydney, NSW Australia.
  • Parini P; NSW Brain Clot Bank, Global Health Neurology Lab & NSW Health Pathology, Sydney, NSW Australia.
  • Andrews RJ; Department of Pathology, Faculty of Medicine & Surgery, University of Malta, Msida, Malta.
  • Bauchner H; Faculty of Medical Sciences, University Goce Delcev, Stip, North Macedonia.
  • Golubnitschaja O; CuraMed Tagesklinik Nürnberg GmbH, Nuremberg, Germany.
EPMA J ; 15(2): 149-162, 2024 Jun.
Article de En | MEDLINE | ID: mdl-38841615
ABSTRACT
Non-communicable chronic diseases (NCDs) have become a major global health concern. They constitute the leading cause of disabilities, increased morbidity, mortality, and socio-economic disasters worldwide. Medical condition-specific digital biomarker (DB) panels have emerged as valuable tools to manage NCDs. DBs refer to the measurable and quantifiable physiological, behavioral, and environmental parameters collected for an individual through innovative digital health technologies, including wearables, smart devices, and medical sensors. By leveraging digital technologies, healthcare providers can gather real-time data and insights, enabling them to deliver more proactive and tailored interventions to individuals at risk and patients diagnosed with NCDs. Continuous monitoring of relevant health parameters through wearable devices or smartphone applications allows patients and clinicians to track the progression of NCDs in real time. With the introduction of digital biomarker monitoring (DBM), a new quality of primary and secondary healthcare is being offered with promising opportunities for health risk assessment and protection against health-to-disease transitions in vulnerable sub-populations. DBM enables healthcare providers to take the most cost-effective targeted preventive measures, to detect disease developments early, and to introduce personalized interventions. Consequently, they benefit the quality of life (QoL) of affected individuals, healthcare economy, and society at large. DBM is instrumental for the paradigm shift from reactive medical services to 3PM approach promoted by the European Association for Predictive, Preventive, and Personalized Medicine (EPMA) involving 3PM experts from 55 countries worldwide. This position manuscript consolidates multi-professional expertise in the area, demonstrating clinically relevant examples and providing the roadmap for implementing 3PM concepts facilitated through DBs.
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: EPMA J Année: 2024 Type de document: Article Pays de publication: Suisse

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: EPMA J Année: 2024 Type de document: Article Pays de publication: Suisse